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Background: Treatment of isolated calf muscle vein thrombosis (ICMVT) is controversial. There are no data from
prospective, controlled studies. Objective of this article was to compare the efficacy and safety of a short-term course of
anticoagulation with compression therapy alone.
Methods: We prospectively randomized patients with symptomatic, sonographically proven ICMVT in the soleal and/or
gastrocnemial muscle veins in two treatment arms. The first received low-molecular-weight heparin for 10 days at
therapeutic dosage (nadroparin 180 anti-activated factor X units once daily) and compression therapy for three months,
and the second received compression therapy alone. Primary efficacy endpoint of the study was sonographically proven
progression of ICMVT into the deep veins and clinical pulmonary embolism (PE) as confirmed by objective testing.
Secondary efficacy and primary safety endpoints were major bleeding, death not due to PE, and complete sonographically
proven recanalization of the muscle vein. We assessed transient and permanent risk factors for venous thromboembolism.
Results:One-hundred seven patients were finally ruled eligible for evaluation: 89% outpatients, 11% hospitalized patients.
In the heparin group (n 54) progression to deep vein thrombosis (DVT) occurred in two patients (3.7%), in the group
compression therapy alone (n  53) progression to DVT occurred in two patients (n.s.). No clinical PE and no death
occurred. Thrombus recanalization after 3 months was not statistically significant different between the two study
groups. No major bleeding occurred.
Conclusion: The data do not show superiority of a short-term regimen of low-molecular-weight heparin and compression
therapy in comparison with compression therapy alone in patients with ICMVT in a rather low-risk population. (J Vasc
Surg 2010;52:1246-50.)Isolated calf muscle vein thrombosis (ICMVT) is de-
fined as isolated thrombosis in the soleal and gastrocnemial
calf muscle veins without involvement of the deep stem
veins. It has been a known entity for 30 years,1 but it is
more frequently diagnosed since the shift from venography
to venous compression ultrasound.2-4 The natural history
of isolated calf muscle thrombi has not yet been fully
elucidated. ICMVT has been suggested as being the first
step in the natural course of deep vein thrombosis (DVT)
and as well as in symptomatic pulmonary embolism
(PE),5,6 but there is a high likelihood of spontaneous
regression. Therefore, treatment of ICMVT is controver-
sially discussed in terms of kind of treatment and duration.7
Based on a prior cohort study,8 we hypothesized that a
10-day course of therapeutic low-molecular-weight hepa-
rin (LMWH) could be superior to compression therapy
alone. We tested this hypothesis by means of a randomized,
controlled study.
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1246METHODS
Study participants. All patients presented in the vas-
cular unit of University of Dresden Medical School with
clinical complaints in the lower extremity and suspect of
venous thrombosis.
Inclusion and exclusion criteria. We included con-
secutive patients presenting with symptomatic (less than 14
days), sonographically proven acute ICMVT in the gastroc-
nemial and/or soleal muscle veins prospectively into the
study. Exclusion criteria were: sonographical-proven DVT
in the peroneal or tibial posterior veins and in the proximal
venous segments, symptomatic PE, previous ICMVT and
remaining thrombotic material, known heparin hypersen-
sitivity, renal insufficiency and serum creatinine level above
180 mol/L, malignant hypertension, active, clinically sig-
nificant bleeding, cerebral hemorrhage, recent brain, spi-
nal, ophthalmologic surgery, fibrinolysis within the last 24
hours, active peptic ulcer disease, acute bacterial endocar-
ditis, a known familial bleeding disorder, all other indica-
tion for anticoagulant therapy, life expectancy 3 months,
8 years of age, and missing written informed consent.
Study design. Patients were randomized in two study
groups (block randomization in blocks of 10 according to a
randomization table): 180 antiXa u/kg BW nadroparin
(Fraxodi) once daily for about 10 days and compression
therapy with graduated class-II-calf stockings for 3 months
or compression therapy with graduated class-II-calf stock-
ings for 3 months alone. Therapy was started immediately
after diagnosis. If indicated for other reasons, prophylactic
dosage of heparin was allowed to be continued. Patients
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day 3, days 10-12, after 4 weeks, and 3 months.
Examinations. All examinations were performed in
our vascular diagnostics unit. At baseline examination,
we assessed the following acquired risk factors for throm-
bosis: age, previous venous thrombolic events, trauma,
and/or surgery 4 weeks before inclusion, active cancer,
immobilization for more than 3 days in the 2 weeks
before inclusion, use of oral contraceptives, hormone
therapy, pregnancy, and family history of venous throm-
boembolism (VTE).
Initial laboratory examination included PTT, INR,
hemoglobin, hematocrit, platelets, and creatinine. Platelet
control was performed on days 10-12 to exclude heparin-
induced thrombocytopenia type II. At follow-up examina-
tion, all study participants were asked about symptoms of
VTE.
Baseline and follow-up diagnostic of ICMVT was per-
formed in our vascular diagnostics unit using venous com-
pression ultrasound according to a standardized examina-
tion protocol including the calf muscle veins. The protocol
was validated in a safety study of over 1023 patients with
negative ultrasound and a failure rate of 0.3% after 3
months.9 Ultrasound was performed at inclusion into the
study, at day 3, days 10-12, after 4 weeks, and 3 months.
With the patient supine, the following venous segments
were examined with B-mode compression ultrasonogra-
phy: common femoral vein, proximal part of the great
saphenous vein, deep femoral vein, and superficial femoral
vein. After this, the study participant had to sit up with legs
hanging down. In this position, the following segments
were examined with B-mode compression sonography:
popliteal vein, proximal part of the small saphenous vein,
confluence segment of the posterior tibial and peroneal
veins, proximal and distal parts of the tibial posterior and
peroneal veins, lateral and medial gastrocnemial muscle
veins, lateral and medial soleal sinusoids of the proximal
and distal calf, and distal parts of the great and small
saphenous veins. ICMVTwas defined as a lack of compress-
ibility of one or more segments of either the gastrocnemial
or the soleal muscle vein. Progression into the deep veins
was defined if initially unaffected segments of the popliteal,
tibial posterior, or peroneal veins could not be compressed
with the ultrasound globe. In cases of cinically suspected
PE, a computed tomography (CT)-scan was scheduled.
Recurrent ICMVT was defined as sonographically proven
incompressibility in segments of muscle veins initially un-
affected. Complete recanalization in the follow-up was
defined if a complete compressibility of muscle veins previ-
ously defined as thrombotic was seen. Major bleeding was
defined as a drop of hemoglobin of 2 mmol/L, the need
of transfusion of 2 U packed red cells, and joint, retroper-
itoneal, or cerebral hemorrhage. In cases of death, the cause
of death was confirmed from the death certificate or by
necropsy.
Endpoints. Primary efficacy endpoint of the study was
sonographically proven progression of ICMVT into the
deep veins and clinical PE as confirmed by objective testing.Secondary efficacy and primary safety endpoints were as
follows: (1) major bleeding, defined as drop of hemoglobin
2 mmol/2 mg/dL, transfusion of two packed red cells,
retroperitoneal, joint or cerebral bleeding, (2) death not
due to PE, and (3) complete sonographically proven recan-
alization of the muscle vein.
Ethics. The study protocol was approved by the insti-
tutional ethics committee of the University of Dresden
Medical School, Dresden, Germany. Written informed
consent was obtained from all participants.
Statistical methods. Sample size calculation was
based on our cohort study, conducted in 2000, including
52 patients with therapeutic nadroparin and 32 patients
with compression therapy in which a progression toDVT in
the compression therapy group of 25% comparing with 0%
in the heparin group was revealed (8). Calculating a reduc-
tion of propagation into the deep veins on heparin from
25% to 5%, 54 patients in each treatment group are required
for a two-sided test with   5% and   10% (StatXact-
4-statistical software, Cytel Software Corporation, Cam-
bridge, Mass).
Differences between patient characteristics and out-
comes were calculated by the Mann-Whitney test and the
two-sided Fisher exact test (release 11.0.1 statistical soft-
ware; SPSS Inc, Chicago, Ill), as appropriate. P values.05
were considered as statistically significant.
RESULTS
Patients. We included 109 patients in the study (40
male/69 female; mean age, 55 years). All patients pre-
sented with isolated calf pain. Of these, 55 had been
randomized into the low molecular weight heparin
(LMWH) group, 54 into the group with compression
therapy alone. We diagnosed 40 ICMVT in the gastrocne-
mial muscle veins (37%), and 69 MVT in the soleal muscle
veins (63%). Ninety-one patients presented as outpatients
(89%) and 12 patients as hospitalized patients (11%). The
analysis of the patient characteristics and the different risk
factors for thrombosis are shown in Table I according to
treatment arms. The patient characteristics between the
two study groups were calculated statistically as not signif-
icantly different with exception of statistically significant
more recent surgery or trauma in the group compression
therapy. Two patients were regarded as study dropouts due
to unwillingness to present at follow-up examinations, one
in every patient group. Therefore, 107 patients were finally
available for evaluation: 54 in the LMWH group and 53 in
the group compression therapy without therapeutic
LMWH.
Outcomes. In both treatment groups, progression
into the deep stem veins occurred in two patients (3.7%,
n.s.). In the heparin group, a 42-year-old female patient
with soleal thrombosis showed symptomatic DVT into the
peroneal veins 10 days after stop of the anticoagulation, and
a 39-year-old male patient with gastrocnemial thrombosis
showed asymptomatic progression into the popliteal vein
18 days after termination of anticoagulation. In the group
compression therapy, only a 61-year-old male patient with
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the popliteal vein 8 days after inclusion into the study, and
an 82-year-old female patient with soleal thrombosis
showed asymptomatic progression into the peroneal veins
31 days after inclusion. All characteristics of patients with
thrombus progression are given in Table II. No clinical PE,
no death, and no major bleeding occurred. No recurrent
isolated MVT was seen in any patient in follow-up sonog-
raphy. Thrombus recanalization was seen in 66% in the
heparin group and in 60% in the group without anticoag-
ulation therapy (n.s.) (Table III).
DISCUSSION
This study represents the first randomized trial on
therapy of symptomatic isolated calf muscle vein thrombo-
sis. We tested the hypothesis that a short course of thera-
peutic LMWH could be superior to compression therapy
alone.
ICMVT is a common finding, well detected by venous
compression ultrasound.10 In a trial on flight-associated
thrombosis, we could show an incidence of 10/1000
asymptomatic ICMVT in a month in a cohort of nontrav-
eling controls performing compression ultrasound at inclu-
sion and 3 to 4 weeks after.11 We conclude that the
incidence of ICMVT is 100 times higher than it is known
for symptomatic DVT.12,13 We assume that most of these
small thrombi disappear completely via natural lysis, but a
fraction will develop as symptomatic with a potential of
progression.14
ICMVT has been associated with progression into the
Table I. Characteristics and risk factors
Therapeutic
nadroparin
(n  54)
Compression
therapy, no
therapeutic
nadroparin
(n  53)
P
value
Sex (m/f ) 24/30 15/38 .083
Age (MW) 54 (/15) 57 (/14) .39
Soleal thrombosis 35 (65%) 43 (81%) .058
Gastrocnemial thrombosis 19 (35%) 10 (19%) .058
Permanent risk factors
Family history VTE 13 (24%) 7 (13%) .15
Hormone therapy 5 (9%) 6 (11%) .73
Cancer 1 (2%) 4 (7.5%) .16
Previous VTE 11 (20%) 11 (21%) .96
Oral contraception 7 (13%) 4 (7.5%) .36
Factor-V-Leiden 3 (5.55%) 4 (7.54%) .92
Prothrombin mutation 1 (1.85%) 0 .60
Protein C deficiency 0 0
Protein S deficiency 1 (1.85%) 3 (5.66%) .58
AT III deficiency 0 0
Transient risk factors
Immobilization 7 (13%) 12 (23%) .19
Recent travel 8 (15%) 6 (11%) .59
Pregnancy 0 0
Trauma/surgery 11 (20%) 25 (47%) .03
VTE, Venous thromboembolism.deep stem veins as well as to symptomatic PE.7,8 WhetherICMVT should be treated at all, and if so which treat-
ment regimen is appropriate, remains highly controver-
sial. MacDonald and coworkers followed symptomatic
ICMVT with ultrasound controls. They proved a progres-
sion rate from ICMVT to proximal DVT of 3% in a
3-month follow-up in a cohort followed by duplex sonog-
raphy without any treatment at all.15 However, as a weak-
ness of this study, the investigators could complete the
3-month follow-up in only 65% of the included patients
and the mortality during follow-up was very high (12%).
The incidence of death from PE remained uncertain be-
cause autopsy was not performed.
A further study published by Gillet and coworkers
showed in 18.8% of 128 patients with symptomatic
ICMVT at least one VTE recurrence in a midterm
follow-up (mean, 26.7 months).16 The authors adminis-
tered at least 1 month of anticoagulation at a therapeutic
dosage. In cases of incomplete recanalization after 1
month, they extended anticoagulation for approximately
another 2 months. There are no further data on therapy of
ICMVT available at this time.
The results of the present study are in contrast to the
results from a prospective cohort study performed at our
institution before proving a statistically significant benefit
in preventing thrombus progression to the deep stem veins
by administering 10 days LMWH to patients.8 However,
comparing the study patient data showed more ongoing
risk factors for DVT in the former published cohort study.
In the present study, the number of patients with a low risk
for VTE was quite high; active cancer was seen in only
4.67% of the study population (21.42% in the cohort study)
and ongoing immobilization in 22.64% of the participants
(37.5% in the cohort study).
Limitations. A certain influence on the sonographer
cannot be completely excluded. Unfortunately, the study
represents a rather low-risk population for thrombosis.
Only 10.72% of the included participants were hospitalized
patients with a higher risk for VTE. Imaging tests for PE
were performed only if the patient had symptoms. It is well
known that an important percentage of PE cases are sub-
clinical, and this may have an influence toward lower rates
of PE diagnosis.
How to treat ICMVT? Obviously, ICMVT is a
rather benign finding. Nevertheless, we would recom-
mend to examine the calf veins and to look for these
small calf clots. Natural history shows that 90% of DVT
are of the ascending type with a potential for embo-
lism.17 According to the literature, the rate of DVT
propagating from distal to proximal is between 0% and
25%. The question is how to identify these patients with
a risk for thrombus progression. On the other hand, a
risk of overtreatment has to be considered.18 Therefore,
we would like to approve an individual approach. Our
data show that in low-risk patients without active cancer,
anticoagulation is not necessary. We would recommend
in patients with a transient risk a compression ultrasound
control 1 week after diagnosis. In a case of propagation
to calf-DVT or in the popliteal or femoral veins we would
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multiple risk factors or in patients with active cancer
alone, we would like to start a short-term regimen of
LMWH (for example 4 weeks at a therapeutic dosage), in
patients with persistent active cancer, for a longer dura-
tion.
A compression therapy with calf stockings class II is
able to improve venous outflow. Possibly, there is a benefit
for the patient to accomplish freedom from pain earlier. In
our study, no patient showed any clinical complaints after 3
months. However, we have no clear evidence for this
assumption.
CONCLUSION
We conclude that patients with symptomatic ICMVT
without ongoing risk factors do not benefit from short-
term anticoagulation. Patients with ongoing risk factors
have to be studied again. It is anticipated that short-term
anticoagulation for about 10 days is too short in these
patients and should be administered for about 4 weeks.
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Therapeutic
nadroparin
10 days
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Progression Peroneal veins
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Previous venous thromboembolism 0
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Immobilization 0
Oral contraception 1
Recent travel 0
Trauma/surgery 0
Factor-V-Leiden heterozygous 0
Table III. Outcomes of both study groups
Therapeutic
nadroparin
(n  54)
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therapy, no
therapeutic
nadroparin
(n  53)
P
value
Progression to DVT 2 (3.7%) 2 (3.8%) .99
PE 0 0
Death 0 0
Major bleeding 0 0
Complete
recanalization
36 (66.6%) 32 (60.4%) .23
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